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Abstract
Background: Effective target therapies for intrahepatic cholangiocarcinoma (ICC) have not been identified so far.
One of the reasons may be the genetic evolution from primary (PR) to recurrent (REC) tumors. We aim to identify
peculiar characteristics and to select potential targets specific for recurrent tumors.
Eighteen ICC paired PR and REC tumors were collected from 5 Italian Centers. Eleven pairs were analyzed for gene
expression profiling and 16 for mutational status of IDH1. For one pair, deep mutational analysis by Next Generation
Sequencing was also carried out. An independent cohort of patients was used for validation.
Results: Two class-paired comparison yielded 315 differentially expressed genes between REC and PR tumors.
Up-regulated genes in RECs are involved in RNA/DNA processing, cell cycle, epithelial to mesenchymal
transition (EMT), resistance to apoptosis, and cytoskeleton remodeling. Down-regulated genes participate to
epithelial cell differentiation, proteolysis, apoptotic, immune response, and inflammatory processes. A 24 gene
signature is able to discriminate RECs from PRs in an independent cohort; FANCG is statistically associated
with survival in the chol-TCGA dataset. IDH1 was mutated in the RECs of five patients; 4 of them displayed
the mutation only in RECs. Deep sequencing performed in one patient confirmed the IDH1 mutation in REC.
Conclusions: RECs are enriched for genes involved in EMT, resistance to apoptosis, and cytoskeleton remodeling. Key
players of these pathways might be considered druggable targets in RECs. IDH1 is mutated in 30% of RECs, becoming
both a marker of progression and a target for therapy.
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Background
Intrahepatic cholangiocarcinoma (ICC) is an aggressive
malignancy arising from epithelial cells of the bile ducts
and is considered the second most common liver cancer
type. Limited success in the clinical management and a
persistent increase in the incidence world-wide have
made ICC one of the most lethal and fastest growing
malignancies. In the last three decades, a general incre-
ment of ICC incidence was registered in the Western
countries, and in particular in Italy [1, 2]. Chronic
inflammation processes, such as cholangitis/primary
sclerosing cholangitis (PSC), secondary biliary cirrhosis,
choledocholithiasis, hepatolithiasis, cholecystitis, as well
as HCV and HBV infections promote ICC arising and
progression [3–6]. Conventional chemotherapy, based
on combination of gemcitabine (GEM) and platinum
compounds, and radiotherapy, to date, are not effective
in improving long-term survival [7, 8]. Moreover,
primary or acquired resistance is inevitable and no
second-line chemotherapy has demonstrated efficacy. It
is known that 5-years survival rate of ICC patients re-
mains low, between 25 and 35% in most of the case
series. Literature data showed that ICC recurrences
occur in about half of the patients after surgery with
* Correspondence: caterina.peraldoneia@ircc.it; francesco.leone@ircc.it
†G. Chiorino and F. Leone contributed equally to this work.
1Medical Oncology Division, Candiolo Cancer Institute - FPO, IRCCS, Str. Prov.
142, km 3.95, 10060 Candiolo, Turin, Italy
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Peraldo-Neia et al. BMC Genomics  (2018) 19:440 
https://doi.org/10.1186/s12864-018-4829-0
curative intent, frequently during the first year and
usually in the liver [9].
In the last years, different molecular studies were con-
ducted using intensive high-throughput techniques (i.e. gene
expression and microRNA profiling, deep-sequencing), to
broaden the knowledge on the biological aspects of ICC
progression and to identify potential molecular targets.
Genomic and molecular mechanisms involved in the onset,
progression as well as in chemotherapy resistance in ICC
are poorly documented. Preclinical investigations showed
the involvement of oncogenic pathways in cholangiocarci-
nogenesis; among them, the overexpression of EGFR,
HER2, VEGFR and its ligand, MET, signaling pathways,
which cause a dysregulation of downstream effectors, such
as Ras/Raf/Mek/Erk and PI3K/Akt/PTEN axes [10–12].
Recently, using gene profiling techniques, Sia and collabora-
tors [13] demonstrated that ICC could be stratified on the
bases of molecular characteristics, which correlate with dif-
ferent prognosis. One hundred and forty-nine ICC were
classified in two main classes according to their gene expres-
sion profiles; an inflammation class, associated to a “good”
prognosis, and a proliferation class, associated to a worse
prognosis [13]. In a work of Andersen and collaborators,
104 ICC samples were analyzed by gene expression profiling
and the two prognostic groups were confirmed [14].
Recently, genomic analyses were conducted on primary ICC
tumors by mutational profiling using different techniques,
defining a broad range of mutations, according to the co-
horts analyzed. The most commonly observed alterations
were within TP53, KRAS, PI3K, BRAF, SMAD4, IDH1,
IDH2, NRAS, ARID1A, PTEN, CDKN2A, CDK6, ERBB3,
MET, BRCA1, BRCA2, NF1, PTCH1, and TSC, with variable
percentages due to the heterogeneity of the case stud-
ies [12, 15–17]. These data have been studied to plan
clinical trials aimed at inhibiting specific targets, alone or
in combination with standard chemotherapy. However,
the obtained results are modest and not of impact.
A key role in tumorigenesis seems to be played by mu-
tant IDH1. IDH1 mutation causes an impaired produc-
tion of α-KG in favour of the oncometabolite 2-HG [18];
in particular, it acts as a competitor of α-KG, causing a
hypermethylation of histones and of DNA and promot-
ing epigenetic alterations, all phenomena typically found
during progression and metastatic processes. The role of
IDH1 as prognostic marker is controversial; literature
data demonstrated that IDH1 mutations correlated with
good prognosis in brain tumors, such as glioma, glio-
blastoma and anaplastic astrocytoma [19]. On the con-
trary, in acute myeloid leukemia (AML) and in ICC it
seems that the presence of mutations did not affect the
overall survival (OS) and progression free survival (PFS)
[12, 20]. It has been demonstrated that ICC patients are
frequently mutated (about 25%) in IDH1 hot-spots [21].
A recent work of Saha and collaborators demonstrated
that IDH1 mutations promoted ICC by blocking hepato-
cyte differentiation with an increased number of hepatic
progenitors susceptible to other mutations [22]. Further,
patients harboring IDH1 mutations had a distinct tran-
scriptional signature enriched for hepatic stem cell
genes, identifying a particular subclass of ICC patients
[23]. In preclinical models, IDH1 mutated cell lines were
highly responsive to Src inhibitors, such as Dasatinib
and Saracatinib, suggesting potential targeted therapies
[24]. Recently, different preclinical studies aimed at
studying the efficacy of IDH1 inhibitors have been per-
formed. Further, phase I, II and III clinical trials were
planned and are ongoing to test the safety and efficacy of
IDH1 inhibitors in different malignancies, such as glioma,
cholangiocarcinoma, AML (NCT02074839, NCT02073994,
NCT02719574, NCT02989857).
The identification of the peculiar molecular alterations
of recurrent lesions is required due to the high rate of
local recurrence of this tumor [25]. To date, there are
only few data regarding the mechanisms involved in re-
current disease. For this reason, in this work, we have
molecularly characterized paired primary/recurrent ICC
tumors in order to provide a panel of markers (mutated
or deregulated genes) involved in the progression
process of this subtype of tumors as well as of new suit-
able targets for therapy.
Methods
Patients
Eighteen pairs of formalin fixed (ID #1-#18), paraffin em-
bedded (FFPE) primary and recurrent ICC tumors were
collected from 5 different Italian centers. The independent
cohort is constituted by 13 fresh ICC tumors (ID#19-#31),
10 PRs (named CHC001-PR to CHC024-PR), 3 RECs tu-
mors (CHC002-REC, CHC012-REC, and CHC017-REC)
and 7 ascites samples (ID #33-#38), named PARA-2 to
PARA-11, (where cancer cells were isolated from ascites
liquid obtained by paracentesis procedure), obtained from
different patients. This cohort was analyzed separately for
gene expression profiling and mutational analysis of
IDH1, assuming that PARAs are progressive disease and
consequently they could be assimilated to recurrences.
Additional file 1: Table S1 summarizes patient clinical and
pathological characteristics, and the analyses performed.
The median age of patients is 65, ranging from 41 to 84;
24 females and 14 males were analyzed. The two inde-
pendent cohorts were homogeneous in terms of gender
(Fisher’s Exact test p-value = 0.7), age at diagnosis and
time to recurrence (Student T-test p-values = 0.5 and 0.2,
respectively).
Nucleic acids extraction and quality control
Total RNA was extracted from FFPE tissues using the
miRNeasy FFPE mini kit, following the manufacturer’s
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instructions. Briefly, RNA quantity was evaluated by
Nanodrop, while the quality was assessed by qRT-PCR
testing the Ct of two different amplicons of ACTB. Only
for 11 couples, the RNA had an acceptable quality to
perform further experiments.
DNA was extracted using Qiamp DNA FFPE kit, fol-
lowing manufacturer’s instructions. Briefly, tumor slides
were stained with Hematoxylin and Eosin: tumor areas
were circled by a pathologist. Representative images of
H/E staining are shown in Additional file 2: Figure S1.
Representative tumor areas were scraped, deparaffi-
nized by xylene, rehydrated, subsequently treated with
proteinase K and then purified using columns. Total
RNA of fresh frozen tissues and tumor cells obtained by
paracentesis was extracted by Absolutely RNA miRNA
kit (Agilent Technologies), while DNA was extracted by
QiAmp DNA mini kit (Qiagen), following manufac-
turer’s protocols.
cDNA mediated annealing, selection, extension and
ligation (DASL) assay
Total RNA extracted from FFPE samples was retrotran-
scribed to cDNA using oligo-dT18 and random nanomer
primers, byotinilated and bound to streptavidin particles.
The reactions of labeling with the single color Cy3,
denaturation, and hybridization on Illumina Human
Reference 8 BeadArrays were conducted according to
the manufacturer’s instruction. The slides were washed
and scanned using the Illumina BeadArray Reader
(Illumina, San Diego, CA).
Gene expression analysis (GEP) by Agilent platform
For GEP analysis, Low Input Quick Amp Labeling Kit,
one-color kit (Agilent Technologies) was used to amplify
and label 100 ng of total RNA. Six hundred ng were
hybridized on SurePrint G3 Human Gene Expression
8x60K v2 glass arrays. After arrays scansion, images were
analyzed by the Feature Extraction Software from
Agilent Technologies (version 10.7); raw data were then
processed using the LIMMA (LInear Models for Micro-
array Analysis) package from Bioconductor [26].
Microarray data analysis
Raw data intensities were loaded into R statistical envir-
onment. The normexp method was used for background
correction with an offset of 50 and the quantile method
for normalization. To remove batch effect between sub-
sets of experiments, the combat function was applied to
the dataset [27].
LIMMA was then used to identify differentially
expressed genes in recurrent vs primary ICC samples,
using a paired statistics for paired samples of the first
tested cohort or unpaired statistics for the independent
one [26]; p-values were adjusted for multiple testing by
using the Benjamini-Hochberg correction [28]. TMev
(http://mev.tm4.org) and hclust R function were used to
perform hierarchical clustering of genes/samples using
either selected genes or the global gene expression pro-
filing and to carry out principal component analysis
(PCA). MetaCore version 6.29 (Thomson Reuters) was
used for network and pathway maps analysis. GSEA was
used to evaluate significant enrichment in predefined cu-
rated sets of genes from online pathway databases and
publications in PubMed [29]. The weighted voting algo-
rithm and leave-one-out cross validation available within
the SET tool (Signature Evaluation Tool) were used to
evaluate the discrimination power of our expression
signature on the validation set [30]. The SET algorithm
allows re-evaluation and re-adjustment of the discrimin-
ation power of a given signature by selecting/de-select-
ing genes repeatedly. Microarray data were deposited in
Gene Expression Omnibus (GSE107102).
External dataset
cBioportal was used to download expression profiles of
selected genes in the cholongiocarcinoma TCGA dataset
(33 samples), together with clinical information about
survival [31, 32]. mRNA Expression z-Scores (RNA Seq
V2 RSEM) of the selected genes were used to stratify pa-
tients in two groups according to expression medians. R
survival package was applied to run survival analysis and
generate Kaplan-Meier curves.
Mutational analysis
Quality control and quantification of extracted DNA were
conducted by Bioanalyzer and Qubit, respectively. IDH1
exon 4 was amplified by nested PCR with relative specific
primers (IDH1 external primers: Forward 5’-TGAGCTCTA
TATGCCATCACTGCA-3′, Reverse 5’-CAATTTCAT
ACCTTGCTTAATGGG-3′; IDH1 internal primers: For-
ward 5’-GCAGTTGTAGGTTATAACTATCC-3′; Reverse
5’-TGGGTGTAGATACCAAAAG-3′). The PCR products
were purified using Wizard® SV Gel and PCR Clean-Up
System (Promega, Milan, Italy) and sense and antisense
sequences were obtained by using internal forward and re-
verse primers, respectively. Sequencing was performed by
BigDye Terminator Cycle sequence following the PE Ap-
plied Biosystem strategy and Applied Biosystems ABI
PRISM3100 DNA Sequencer (Applied Biosystem, Forster
City, CA). All mutations were confirmed by two independ-
ent PCR experiments.
Next generation sequencing (NGS)
The Ion Torrent S5 platform was used to perform the
NGS analysis of the Ampliseq CHPv2 which contains
the hot-spot mutations of 50 cancer related genes.
Briefly, DNA of patient #3, both PR and REC, was used
to prepared libraries by Ion AmpliSeq Library kit 2.0
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(ThermoFisher Scientific Waltham, MA) according to
the manufacturer’s protocol. Libraries were then quanti-
fied using Qubit (ThermoFisher Scientific Waltham,
MA; 60 pM of each sample were run and sequenced for
2800 hot-spots of 50 among oncogenes and tumor sup-
pressors. Raw data were analyzed by Ion Reporter soft-
ware (ThermoFisher Scientific Waltham, MA) and
filtered in p-value < 0.001 and coverage of > 400 were
accomplished.
Results
Transcriptomic analysis of paired PRs and RECs ICC
To analyze sample distributions according to their tran-
scriptomic profiles, unsupervised hierarchical clustering
was applied to the global normalized intensity profiles.
As shown in Fig. 1a, PRs and RECs tumors had different
distributions; for some patients, PRs and RECs had simi-
lar profiles, for others the RECs were very distant from
their PR tumors, underlining the high heterogeneity of
these tumors. In particular, four PRs belonged to a dif-
ferent branch arm. Principal component analysis (PCA)
was able to clearly separate primary from recurrent sam-
ples, as shown in Fig. 1b. Then, we refined the analysis,
applying a two-class paired comparison and filtering
data with a cut-off on logFC > 1 or < − 1 and an adjusted
p-value < 0.01, obtaining 315 significant deregulated
genes, of which 65 down- and 250 up-regulated in RECs
versus PRs (Additional file 3: Table S2). Figure 1c shows
the heatmap of this genes signature.
Using Metacore software, we performed an enrich-
ment analysis of pathway maps and process networks.
Additional file 4: Table S3 and Additional file 5: Table S4
describe the first 15 pathways and networks enriched in
up-regulated genes. They were associated to Epithelial to
Mesenchymal Transition (EMT) mediated by Rho alpha,
PI3K and ILK mediated by TGF beta, cytoskeleton re-
modeling by GTPase, anti-apoptotic process mediated
by BAD phosphorylation, and in general cell cycle,
Fig. 1 a Dendrogram obtained from unsupervised hierarchical clustering using Euclidean distance as similarity metrics and ward as linkage method.
Each branch of the dendrogram is represented by the global gene expression profile of samples. The vertical axis indicates the Euclidean distance
between samples/clusters. PR and REC of the same patient are represented with the same color. b Projection of principal components 1 and 3 after
application of PCA on the paired samples cohort. Red squares correspond to primary samples while yellow squares to recurrences. c Unsupervised
hierarchical clustering analysis of 315 significantly deregulated genes in REC vs PR tumors. A red-to-green gradient was used to indicate, for each
gene, levels of up- or downregulation. The logFC values of the entire matrix used for hierarchical clustering are provided as Additional file 3: Table S2
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cytoskeleton remodeling and EMT networks. On the
contrary, down-regulated genes affected in particular,
PTEN signal transduction, immune response, apoptosis
mediated by p53, proteolysis related to cell cycle and
apoptosis, inflammation mediated by IL-6 signaling
(Additional file 6: Table S5 and Additional file 7: Table S6).
The application of Gene Set Enrichment Analysis on
the complete list of pre-ranked genes was not very con-
clusive. However, pre-ranked GSEA on the 315 genes
signature showed a high number of overlapping genes
with the “Liver_cancer_UP” geneset described by Acevedo
and collaborators (Enrichment score 0.38, p = 0.009;
Fisher’s exact test p-value = 0.002; Jaccard Index = 0.022)
as shown in Additional file 8: Figure S2 [29].
Further, restricting the analysis with more stringent
filters (logFC <− 2 or > 2 and p < 0.01) we obtained a
gene signature of 24 deregulated genes, 10 down- and
14 up-regulated, able to separate RECs from PRs tu-
mors (Fig. 2).
These genes could be grouped in four main functional
classes: regulation of apoptosis, (FOXJ2, SEMA3B,
CARD9), cellular migration and motility (CLDN23,
TRIOBP), DNA-RNA processing (FANCG, UBLCP1),
metabolic processes such as glycolysis and fatty acids
metabolism (PECI, PFKM, NDST2, DAO). The transcripts
of this signature were investigated on an independent co-
hort of patients (10 RECs vs 11 PRs, IDs #19-#38, see
Additional file 1: Table S1 and Additional file 9: Table S7);
as shown in Additional file 10: Figure S3, expression fold
changes of 17 out of 24 genes were concordant in the two
cohorts, with 8 genes differentially expressed in a statisti-
cally significant manner in the independent cohort as well.
Further, we applied the 24 genes signature on the val-
idation dataset and we demonstrated that the expression
of 9 genes (NDST2, DAO, FANCG, CARD9, FOXJ2,
SEMA3B, GDAP1L1, TRIOBP, PFKM) is able to distin-
guish PRs from RECs (Fig. 3), with an error rate of 0.15
and p < 0.001. The weights of individual genes are re-
ported in Additional file 11: Table S8.
Finally, the expression profiles of the 9 genes and the
survival information about patients were downloaded
from the cholangiocarcinoma TCGA dataset (n = 33)
available through cBioportal (http://www.cbioportal.org).
Among the genes overexpressed in patients with worst
prognosis, the one mostly associated with survival is
FANCG, with Cox proportional hazard ratio = 3.242 (Fig. 4).
IDH1 is a potential marker of tumor progression
For 16 paired PR and REC ICC tumors, the mutational
analysis of IDH1 exon 4 was conducted. As shown in
Additional file 12: Table S9, five patients (#3, #6, #11, #15
and #18) harbored an IDH1 R132x mutation in the REC
counterpart (31.3%); only in patient #6 (6.25%) the muta-
tion was already present in PR. Figure 5 shows electrophe-
rograms of mutated samples compared to WT one.
In order to confirm the naïve IDH1 mutation identified
by Sanger sequencing in REC tumor, patient #3 was ana-
lyzed by NGS using the AmpliSeq technology on Ion Tor-
rent device. In patient #3, the IDH1 mutation in codon 132
was confirmed in REC tumor, with a 17.37% of frequency
(p = 0.0001) and PR counterpart resulted WT. Overall, the
mutational profile is partially overlapping between PR and
REC, even if a higher number of missense mutations was
identified in PR. Additional file 13: Table S10 summarizes
Fig. 2 Unsupervised clustering analysis of 24 significantly deregulated genes in 13 REC tumors compared to 11 PR tumors. Tmev software was
used, with Euclidean distance as similarity metrics and complete linkage as linkage method. Log Intensities of each gene were standardized by
median centering and dividing by standard deviation. Red/green rectangles indicate expression higher/lower than the median, respectively
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the mutational pattern (exonic missense and synonymous,
intronic) of patient #3. Among them, KDR, APC, RB1,
TP53, IDH1 are already described [33].
Discussion
In this work, we demonstrated that recurrent intrahepa-
tic cholangiocarcinomas (REC ICC) are distinguishable
from their primary tumors (PR) by the transcriptomic
enrichment in genes involved in proliferation, motility
and migration, apoptosis resistance, and epithelial-to
mesenchymal transition. Further, mutated IDH1 hotspot
(codon 132) emerged in about 30% of REC tumors sug-
gesting that it could be a putative marker of progression.
Results obtained by the comparison of matched REC/PR
ICC suggest that recurrent lesions could be molecularly
different from their primary tumors due to a clonal se-
lection toward drug resistant and more malignant tumor
cells in RECs. Mutational analysis by Sanger revealed
that 4 patients harbored IDH1 R132x mutations in
RECs, but not in the PRs; NGS analysis performed in a
PR-REC pair showed that IDH1 mutation was gained in
REC, confirming our direct sequencing results. How-
ever, other missense mutations found in PR were
lost, suggesting that a clonal sieving occurred in
REC. As a matter of fact, Sanger sequencing has
limitations; small DNA fragments could be analyzed
with a single reaction and some mutations may re-
sult undetectable, due to the low clonal representa-
tion. On the contrary, NGS is more sensitive and
covers broad range spectra of mutations with a low
amount of DNA and should be preferred as a
screening method. However, our data supports the
heterogeneous nature of this tumor type, both intra-
and inter-patients. Many factors, including treatment,
could concur in the evolution of the tumor. For the
choice of second-line treatments it should be consid-
ered that responsive tumor clones are inhibited by
previous therapy and concurrently disease progression is
sustained by chemotherapy-resistant clones.
Fig. 3 Predictive role of 9 out 24 genes of the signature. The expression of these genes is able to clearly separate PRs (square) and RECs (circle) in
the validation cohort of patients. Signal to noise scores provided by SET are shown for each gene in Additional file 11: Table S8
Fig. 4 Kaplan-Meier curves for 33 patients from the TCGA
cholangiocarcinoma external dataset, with survival information
available. Patients are divided in two groups according to FANCG
expression. Red curve: FANCG expression higher than the median.
Black curve: FANCG expression lower than the median. Log-rank test
p-value = 0.0544. Cox proportional hazard ratio = 3.242
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According to microarray data, PRs and RECs of the
same patient could have very similar or distinct profiles.
This finding is enhanced in particular in those patients
for whom we had two RECs; in one case, the two RECs
are comparable and the expression profile is far from
their PR, but for the other patient, one REC is near to
PR while the other one displays a different pattern of ex-
pression. Further, the complexity of these tumors is
highlighted not only by the heterogeneity identified be-
tween RECs and their PRs, but also within different bi-
opsies of the same lesion [34]. Globally, we found an
increased expression of genes involved in nucleic acids
processing, transcription of RNA and non-coding RNA,
and angiogenesis regulation, with a concomitant
down-regulation of genes related to epithelial cell differ-
entiation. The down-regulation of epithelial cell differen-
tiation genes suggested that the epithelial-like phenotype
is switched towards a mesenchymal-like. This data is
confirmed by pathways and maps analyses, with an en-
richment of up-regulated genes involved in EMT, in par-
ticular induced by TGF-beta. In agreement with several
evidences in other types of cancer [35–37], these data
confirmed that EMT is one of the crucial steps of recur-
rence and drug resistance. We also described an
up-regulation of genes involved in cytoskeleton remodel-
ing and cell cycle regulation in REC tumors. Many stud-
ies described the close interconnection among these
events; the remodeling of extracellular matrix and
reorganization of cytoskeleton, along with expression of
mesenchymal markers and reduction of epithelial
markers, are crucial events during tumor progression to-
ward a more aggressive, proliferating and drug resistant
phenotypes [38, 39]. We showed that a 24 genes signa-
ture is able to distinguish RECs from PRs in the main
cohort of analysis. The trend of these genes is partially
confirmed on an independent cohort of patients consti-
tuted by fresh frozen PR or REC ICC tumors and tumor
cells obtained from ascites liquid of ICC patients in pro-
gressive disease (PARAs). The two cohorts are small,
which could limit the robustness of our results, but they
are homogeneous in terms of baseline characteristics
(sex, age at diagnosis) and time to recurrence. They are
mainly composed of T2 stage tumors, with ascites in-
cluded in the validation cohort only, which might be po-
tentially confounding. However, in the latter cohort the
expression of 9 of the signature genes is able to discrim-
inate RECs from PRs in a statistically significant manner.
Moreover, these molecules might represent novel
therapeutic targets. Namely, CARD9 is a marker of
tumor progression and poor prognosis in hepatocarci-
noma (HCC), B cell lymphoma, and clear cell renal
carcinoma [40–42] and promotes metastatization acti-
vating metastasis-associated macrophages (MAM) [43].
Besides, the higher expression of FANCG suggested that
REC tumors displayed increased DNA damage and
activated DNA repair. The downregulation of FANCG
was associated with effective treatment with GEM and
radiolabeled Trastuzumab in tumor xenograft model of
Fig. 5 Representative electropherograms of mutated samples in the hot-spot codon 132 of IDH1
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disseminated intraperitoneal disease (46). Moreover, we
found an up-regulation of PIK4CA which is involved in
proliferation and chemoresistance in other tumors, such
as medulloblastoma [44]. The same trend of expression
was revealed for TRIOBP, already described in pancreatic
cancer where is involved in cell motility and migration
through cytoskeleton remodeling [45, 46]. Interest-
ingly, the emergence of IDH1 in about 30% of REC
patients suggested that it could be considered not
only a marker of progression but also a potential tar-
get for tailored therapy. In fact, it has been demon-
strated that IDH1 mutation promoted sensitivity to
the multitarget inhibitor Dasatinib [24]. Moreover,
mutated-IDH1 targeting agents are now under clinical
investigation in different solid tumors, including ICC.
As an example, BAY1436032 targeting the hot-spot
mutation R132x is now tested in patients with ad-
vanced solid tumors enrolled in one open-label,
non-randomized, multicenter phase I-II clinical trial
(NCT02746081). Of main interest, the effect of
AG-120 is now compared to placebo in the phase III,
multicenter, randomized double-blind ClarIDHy trial
on non-resectable/metastatic cholangiocarcinoma.
Conclusions
In conclusion, our data on transcriptomic and mutational
status of REC ICC suggest that a personalized approach,
in which tumor molecular/genetic characterization are
followed from diagnosis to disease progression, is advis-
able not only for prognostic purposes, but also to identify
the emergence of other druggable targets after first-line
treatment failure.
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